Victory Capital Management
ABCL icon

Victory Capital Management’s AbCellera Biologics ABCL Stock Holding History

Victory Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-26,314
Closed -$170K – 2517
2023
Q2 		$170K Sell
26,314
-148,105
-85% -$1.01M ﹤0.01% 2227
2023
Q1 		$1.32M Buy
174,419
+160,975
+1,197% +$1.46M ﹤0.01% 1556
2022
Q4 		$136K Buy
+13,444
New +$155K ﹤0.01% 2319

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Victory Capital Management's ABCL Position: Q3 2023 in Review

Victory Capital Management sold out of AbCellera Biologics (ABCL) in Q3 2023, closing a stake of 26,314 shares — an estimated $170K sold.

Victory Capital Management first reported a position in ABCL in Q4 2022 and held it in 3 quarters. The position peaked at $1.32M in Q1 2023. 138 funds tracked by Wall St. Rank hold ABCL as of Q3 2023.

  • Victory Capital Management reported no remaining AbCellera Biologics position as of Q3 2023 after selling out during the quarter.
  • Victory Capital Management sold 26,314 AbCellera Biologics shares in Q3 2023, an estimated $170K.
  • Victory Capital Management first reported a position in AbCellera Biologics in Q4 2022 and held it in 3 quarters.
  • Victory Capital Management's AbCellera Biologics position peaked at $1.32M in Q1 2023.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2023.

Based on Victory Capital Management's 13F filing for Q3 2023, filed 6 Nov 2023.